RankingsPricing
  1. US-listed companies
  2. Viridian Therapeutics, Inc.\DE
  3. Raw

Viridian Therapeutics, Inc.\DEVRDN

Market cap
$2.6B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Cash and cash equivalents-----254642156103100
Short-term investments--------269375618
Prepaid Expense and Other Assets, Current0321,0000333237921
Unbilled revenue - related party--------00-
Total current assets7124526530130200431486738
Property and equipment, net11-11100121
Operating lease right-of-use asset------02222
Other assets---00-11111
Total assets8134526630131204435490742
Accounts payable0242,0000111121422
Accrued Liabilities, Current0133451011192445
Contract with Customer, Liability, Current------0-000
Total current liabilities22547101114332748
Long-term debt, net--------52021
Deferred revenue - related party--------110
Other liabilities024,000-00-11112
Total liabilities---1415151116404871
Series A Preferred Stock------181118857861
Series B Preferred Stock-------1657128128
Preferred stock-----------
Common Stock, Value, Issued0106,000000000011
Additional paid-in capital1328301321771842184127419611,478
Accumulated other comprehensive income (loss)-----0--0-0-00-0
Accumulated deficit-7-17,968,000-31-94-126-168-279-358-488-726-996
Series A Preferred Stock------181118857861
Series B Preferred Stock-------1657128128
Total stockholders’ equity610-0395116120188395442672
Total liabilities and stockholders’ equity8134526630131204435490742